New Investor Ideas in Energy - (OTCQX: $PTHRF) (TSXV: $GASX.V) (TSX: $AXL.V) (Nasdaq: $KGEI)

New Investor Ideas in Energy - (OTCQX: $PTHRF) (TSXV: $GASX.V) (TSX: $AXL.V) (Nasdaq: $KGEI)

 

New stocks added to Green & Eco-friendly: (TSX: $CVW.V) (TSX: $KEI.TO) (TSX.V: $JEV.V) (TSXV: $REVV.V) (CSE: $HPSS.CN) (NASDAQ: $TURB) (CSE: $PLAS.CN)

 

 

 

December 15, 2023 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Energy and Green & Eco-Friendly. Today’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at  https://www.investorideas.com/news/2023/main/12151Stocks.asp

 

The newest energy companies are involved in oil and gas exploration.

 

The latest green companies are involved in Oil remediation technology, Renewable Energy, Hydrogen, Batteries/Energy Storage Backup, Recycling, Solar, Wind and Sustainable Plastics.

 

New Stocks Added the Energy Directories:

Pantheon Resources PLC (OTCQX: PTHRF; LSE: PANR) is an AIM listed Oil & Gas company focused on developing the Ahpun and Kodiak fields located on state land on the Alaska North Slope ("ANS"), onshore USA where it has a 100% working interest in 193,000 acres. Certified contingent resources attributable to these projects exceeds 1 billion barrels of marketable liquids, located adjacent to Alaska’s Trans Alaska Pipeline System ("TAPS").

 

NG Energy International Corp. (OTCQX: GASXF; TSXV: GASX) is a publicly traded E&P company on a mission to provide a clean and sustainable solution to Colombia's energy needs. The Company intends on executing this mission by producing and bringing gas to the premium priced Colombian gas market from SN-9, a 311,353 acres block which is adjacent to Canacol's Nelson field, as well as Maria Conchita, a 32,518-acre block located in the region of La Guajira. NGE's team has extensive technical expertise and a proven track record of building companies and creating value in South America.

 

Arrow Exploration Corp. (TSX:AXL.V; LSE:AXL) (operating in Colombia via a branch of its 100% owned subsidiary Carrao Energy S.A.) is a publicly traded company with a portfolio of premier Colombian oil assets that are underexploited, under-explored and offer high potential growth. The Company's business plan is to expand oil production from some of Colombia's most active basins, including the Llanos, Middle Magdalena Valley (MMV) and Putumayo Basin. The asset base is predominantly operated with high working interests, and the Brent-linked light oil pricing exposure combines with low royalties to yield attractive potential operating margins. By way of a private commercial contract with the recognized interest holder before Ecopetrol S.A., Arrow is entitled to receive 50% of the production from the Tapir block. The formal assignment to the Company is subject to Ecopetrol's consent. Arrow's seasoned team is led by a hands-on executive team supported by an experienced board.

 

Kolibri Global Energy Inc. (Nasdaq:KGEI; TSX: KEI) is a North American energy company focused on finding and exploiting energy projects in oil and gas. Through various subsidiaries, the Company owns and operates energy properties in the United States. The Company continues to utilize its technical and operational expertise to identify and acquire additional projects in oil, gas and clean and sustainable energy.

 

New Stocks Added the Green & Eco-Friendly Directories:

CVW CleanTech Inc. (TSX:CVW.V) is a clean technology innovator working to develop sustainable technology solutions. The Company has developed a suite of proprietary technologies called Creating Value from Waste™ that recover bitumen, solvents, critical minerals, and water from oil sands froth treatment tailings while significantly reducing tailings pond emissions and enhancing tailings management. CVW CleanTech has invested over $100 million and over 15 years to advance the CVWTM technology to ready-to-deploy status. This technology has been supported by large scale integrated piloting and progressive commercial engineering studies resulting in 20 active patents. The development of the Company's technology has been supported by the Government of Alberta and the Federal Government along with oil sands industry partners.

 

Renergen Limited (REN.JO; ASX:RLT) is an integrated alternative and renewable energy business that invests in early stage energy projects across Africa and emerging markets. Renergen is an emerging helium and LNG producer with production rights to a unique renewable gas resource at its Virginia Gas Project.

 

Genex Power Limited (GNX.AX) is focused on developing a portfolio of renewable energy generation and storage projects across Australia.

 

Jericho Energy Ventures Inc. (TSX.V:JEV; OTC:JROOF) is an energy company positioned for the current energy transitions; owning, operating and developing both traditional hydrocarbon JV assets and advancing the low-carbon energy transition, with active investments in hydrogen. Our wholly owned subsidiary, Hydrogen Technologies, delivers breakthrough, patented, zero-emission boiler technology to the Commercial & Industrial heat and steam industry. We also hold strategic investments and board positions in H2U Technologies (a breakthrough electrocatalyst and low-cost electrolyzer platform) and Supercritical Solutions (developing the world's first, high pressure, ultra-efficient electrolyzer). Jericho also owns and operates long-held producing oil and gas JV assets in Oklahoma which it is currently developing from cash flows in an effort to further increase production into the current elevated commodity price environment

 

ReNu Energy Limited (RNE.AX) is one of Australia’s only listed incubators and accelerators of renewable energy technology and projects. We have several projects underway in our portfolio of companies, ranging from green hydrogen development to energy storage solutions and battery technologies, to renewable energy tracing and generation. From early stage emerging technologies to proven commercial pilots, each company is at a different stage in its journey.

 

ReVolve Renewable Power Corp. (OTCQB: REVVF; TSXV: REVV) was formed in 2012 to capitalize on the growing global demand for renewable power. Revolve develops utility-scale wind, solar and battery storage projects in the US, Canada and Mexico with a portfolio of approx. 2,838MW under development. The Company has a second division, Revolve Renewable Business Solutions which installs and operates sub 20MW "behind the meter" distributed generation (or "DG") assets. Revolve Renewable Business Solutions currently has an operating portfolio of 6MW with an additional 3MW under construction phase and 156MW under development. Revolve has an accomplished management team with a demonstrated track record of taking projects from "greenfield" through to "ready to build" (or "RTB") status and successfully concluding project sales to large operators of utility-scale renewable energy projects. To-date, Revolve has developed and sold over 1,550MW of projects. Revolve is targeting 5,000MW of utility-scale projects under development in the US, Canada and Mexico, and in parallel is rapidly growing its portfolio of revenue-generating DG (distributed generation) assets.

 

Hybrid Power Solutions Inc. (CSE:HPSS) is a Canadian clean energy company specializing in producing industrial grade clean technology products such as portable power packs and stationary energy storage

 

Turbo Energy S.A. (NASDAQ: TURB) is a leading photovoltaic energy storage technology company based in Valencia, Spain. The Company’s focus is on developing innovative solutions that allow end consumers to harness the full potential of solar energy and reduce their electricity costs. With a combination of Artificial Intelligence and advanced technology, Turbo Energy is paving the way towards a more sustainable and energy-efficient future.

 

PlasCred Circular Innovations Inc. (CSE:PLAS.CN) is at the forefront of rebalancing the future of plastics. The company is transforming plastic waste by granting it a valuable second life. With a vision of advancing towards a climate-positive future, PlasCred aspires to be among the largest advanced plastic waste upcycler's in North America and globally. Their groundbreaking patent-pending technology is set to revolutionize the approach to plastic waste management and upcycling. PlasCred is also developing strategic partnerships with CN Rail and Fibreco Export Inc., providing PlasCred with unparalleled logistics support across North America and globally for transportation and handling of plastic waste.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

New #Investor Ideas in #Biotech (Nasdaq: $CADL) (NASDAQ: $PPBT) (Nasdaq: $RYZB) (Nasdaq: $HOWL)

New #Investor Ideas in #Biotech (Nasdaq: $CADL) (NASDAQ: $PPBT) (Nasdaq: $RYZB) (Nasdaq: $HOWL)

 

New #stocks added to #lifesciences, #fintech and #defense directories (NASDAQ: $CELZ) (TSX: $KSI.TO) (Nasdaq: $NMRA) (OTCQX: $RDSNF) (OTCQB: $LVER) (Nasdaq: $OPTX)

 

 

 

December 8, 2023 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Life Sciences, Fintech and Defense. Today’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2023/main/12081Stocks.asp

 

The newest biotech companies are involved in biopharmaceuticals, radiopharmaceutical therapeutics, biological therapeutics, neuroscience programs and medical devices.

 

The latest fintech company is involved in loan management, while the newest defense company is an optics and photonics leader for aerospace and defense products.

 

New Stocks Added the Biotech Directories:

Candel Therapeutics, Inc. (Nasdaq: CADL) Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. This leads to in situ vaccination against the injected tumor and uninjected distant metastases. Candel has established two clinical stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in NSCLC (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma. In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

 

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219, CM24 and IM1240. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing it in a dose escalation as a monotherapy treatment of solid tumors, and in a dose escalation in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both T cells and NK cells to mount a strong, localized immune response within the tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA) 5T4 that is expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. IM1240 has a cleavable capping technology that confines the compound's therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients. The Company's corporate headquarters are located in Rehovot, Israel.

 

RayzeBio, Inc. (Nasdaq:RYZB) is building a vertically integrated radiopharmaceutical therapeutics (RPT) company to treat various cancers, with its lead program in a Phase 3 clinical trial. RayzeBio has created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Much like antibody drug conjugates emerged as a new and transformative treatment modality in certain cancers, the company sees an opportunity for innovative radiopharmaceutical therapeutics to follow a similar path. RayzeBio believes its strategic investments in building a robust product pipeline, development capabilities, and manufacturing infrastructure position the company to be an industry-leading pioneer in the broad application of RPT for cancer.

 

Werewolf Therapeutics, Inc. (Nasdaq:HOWL) is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma.

 

Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) is a biotechnology company dedicated to the advancement of identifying and translating novel immediately deployable FDA registered biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology and orthopaedics.

 

Kneat Solutions (TSX: KSI) a Canadian company with operational headquarters in Limerick, Ireland, develops and markets the next-generation Kneat Gx SaaS platform. Multiple business work processes can be configured on the platform from equipment to computer validation, through to quality document management. Kneat's software allows users to author, review, approve, execute testing online, manage any exceptions, and post-approve final deliverables in a controlled FDA 21 CFR Part 11/ EU Annex 11-compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes globally. Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard.

 

Neumora Therapeutics, Inc. (Nasdaq:NMRA) is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

 

Redsense Medical AB (OTCQX: RDSNF) is born-global medical device innovator established in Sweden. Redsense's mission is to improve the safety and quality of life for dialysis patients worldwide. The group has its main market in the United States as well as sales in Europe and Canada. Redsense promotes patient safety through highly cost-efficient fiber-optic monitoring of the blood access site during hemodialysis. The Redsense System immediately detects Venous Needle Dislodgement (VND) - a potentially life-threatening complication that causes 21 avoidable deaths per week worldwide. In essence, the Redsense alarm provides patients, nurses, and caregivers an extra pair of eyes; always alert, focused on one thing only, never looking away. Redsense products are used in both clinics and at home, daily and nocturnally. Today, the majority of treatments are performed in clinical settings, but home treatment is gaining popularity thanks to lower cost, increased convenience for the patient, improvements in technology and political initiative. The number of patients undergoing hemodialysis several times per week due to chronic kidney disease is approaching 4 million, worldwide. The projected growth rate is six percent annually, driven by ageing population and other factors. Every hemodialysis treatment carries the risk of VND. In the last years more than 1 million treatments have been conducted

 

New Stocks Added the Fintech Technology Directories:

Lever Global Corp. (OTCQB:LVER) is a cutting-edge financial platform dedicated to assisting borrowers in navigating the complexities of loan management. With a suite of innovative tools and a user-centric approach, Lever is redefining the future of financial management.

 

New Stocks Added the Defense Directories:

Syntec Optics Holdings, Inc. (Nasdaq:OPTX) a 20-year optics and photonics leader for scientific and technical instruments and aerospace and defense products, has the mission of keeping American soldiers out of harm’s way, improving patient care and bringing more precision products to the consumer. Syntec Optics, headquartered in Rochester, NY, is one of the largest custom optics and photonics manufacturers in the United States. Operating for over two decades, Syntec Optics runs a state-of-the-art manufacturing facility with extensive core capabilities of various optics manufacturing processes, both horizontally and vertically integrated, to provide a competitive advantage for optics and photonics integrators. Syntec Optics recently launched new products, including Low Earth Orbit satellite optics and lightweight night vision goggle optics.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

Aethlon Medical (NASDAQ: $AEMD) Research/Media Alert: “Expect Focus on Oncology Studies; Cost Containment Efforts”

 

Aethlon Medical (NASDAQ: $AEMD) Research/Media Alert: “Expect Focus on Oncology Studies; Cost Containment Efforts”

 

December 4, 2023 - Investorideas.com (https://www.investorideas.com) a global investor news source covering biotech and medical technology stocks releases a research/media alert for investors following the sector, featuring medical therapeutic company, Aethlon Medical, Inc. (NASDAQ:AEMD). Zacks small-cap research issued a summary of the report, ’Expect Focus on Oncology Studies; Cost Containment Efforts,’ on November 16^th.

 

Link to news/report

https://finance.yahoo.com/news/aemd-expect-focus-oncology-studies-160600342.html

 

Read the full research report

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_11162023_AEMD_Marin.pdf

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2023/biotech/12041Aethlon-Medical-AEMD-Oncology-Studies.asp

 

 

Excerpt:

 

By M. Marin

 

Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely…

 

Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 & knows the company well, in our view. Moreover, including Aethlon, he has had 27 years of CFO level financial responsibility with publicly traded companies. We anticipate increased emphasis on studying the Hemopurifier® in the oncology area, as well as potential cost containment measures when possible, are likely.

 

Mr. Frakes, who was also appointed as a member of the company's board, will continue his responsibilities as CFO. In addition, Guy Cipriani has been named as the company's Chief Operating Officer. He had been Aethlon’s Chief Business Officer prior to assuming the COO role. Mr. Cipriani has resigned from the Aethlon board. We do not anticipate major changes as a result of this management shift, although we believe the company is likely to emphasize its clinical efforts in the field of oncology.

 

… and potential cost containment measures when possible…

 

Mr. Frakes has been with Aethlon since January 2008 and therefore knows the company well, in our view. Moreover, including his role at Aethlon, he has had 27 years of CFO level financial responsibility with publicly traded companies, as noted. We do not anticipate a major shift in strategy as a result of this management change, as noted, other than likely increased emphasis on studying the Hemopurifier® in the oncology area and potential cost containment efforts when possible.

 

Expect cash balance, lowering costs where possible, plus accessing ATM funding will enable company to continue moving Hemopurifier forward towards potential regulatory approval, commercialization

 

We believe lowering costs where possible, plus accessing funding, will enable the company to continue moving the Hemopurifier forward in clinical studies towards potential regulatory approval and commercialization. Under James Frakes’ leadership as CFO, the company put in place an ATM (At The Market offering) to enhance its financial flexibility. AEMD believes its cash balance is sufficient to fund operations for at least a year. We believe lowering costs where possible, plus accessing ATM funding, will enable the company to continue moving the Hemopurifier forward in clinical studies towards potential regulatory approval and commercialization. If Aethlon can demonstrate the Hemopurifier’s ability to improve outcomes of cancer patients suffering from a variety of different cancer types, we would anticipate strong commercial prospects for the device.

 

… majority of patients treated with checkpoint inhibitors do not respond; studying whether Hemopurifier with checkpoint inhibitors can improve overall patient outcomes

 

The company recently received clearance from the Drug Controller General of India (DCGI), which is India’s central drug authority, to conduct a phase 1 safety, feasibility and dose-finding trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment such as Keytruda® or Opdivo®. PD-1, or Programmed Cell Death Protein 1, is a protein found on the cell surface that plays a role in inhibiting immune responses. Treatment such as Keytruda®, a type of immunotherapy, helps to block the PD-1 pathway to prevent cancer cells from hiding and, in turn, help the immune system work. While Keytruda® and other anti-PD-1 monotherapy treatments represent a substantial advance in cancer treatment, with certain tumor types it does not work on the majority of cancer patients.

 

Checkpoint inhibitors such as Keytruda have been used to treat 25+ different types of cancer. By launching a basket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors, AEMD believes it can generate data to support the Hemopurifier’s ability to improve outcomes, when combined with checkpoint inhibitor treatment, in multiple tumor types where cancer associated extracellular vesicles may promote immune suppression and resistance to anti-PD-1 antibodies. Given the Hemopurifier’s demonstrated ability to remove exosomes, management believes the device can be used to affect improved outcomes in a number of cancers.

 

Moreover, by focusing on multiple cancers, the company has also expanded the opportunities for patient enrollment, as well as for building a database to support regulatory approval. By including both Keytruda and Opdivo can also facilitate patient enrollments.

 

About Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water.

Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

New Investor Ideas in AI - (CSE: $AIG.CN) (CSE: $READ.CN) (CSE: $RAIL.CN) (Nasdaq: $TALK) (NASDAQ: $WAVD)

New Investor Ideas in AI - (CSE: $AIG.CN) (CSE: $READ.CN) (CSE: $RAIL.CN) (Nasdaq: $TALK) (NASDAQ: $WAVD)

 

AI stocks on ASX, NEO and OTC - (ASX:DRO) (OTCQB: $SCTC) (NEO: VERS)

 

 

 

December 1, 2023 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in AI Technology. Today’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2023/main/12011Stocks.asp

 

The newest tech companies are all involved in various applications of AI (artificial intelligence) technology.

 

New Stocks Added the AI Technology Directories:

DroneShield Limited (ASX:DRO.AX) provides Artificial Intelligence based platforms for protection against advanced threats such as drones and autonomous systems. We offer customers bespoke counterdrone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime or airborne platforms. Our customers include military, intelligence community, Government, law enforcement, critical infrastructure, and airports globally.

 

Genesis AI (CSE:AIG; OTC:AIGFF) is a proprietary generative AI model in development, building digital twins for real-world natural resources applications. Digital twins can be manipulated and studied in computer generated worlds, with the influence of deep machine learning and neural networks, providing disruptive real-world problem solving. Genesis AI Corp. is pursuing opportunities in the precision geospatial, forestry analytics, mining exploration, carbon sector through AI. The company is also developing tools to help predict forest fire behavior, speed up response times when it most counts, and build more resilient forests through effective management.

 

Legible Inc. (OTCQB: LEBGF; CSE: READ) is a groundbreaking, mobile-centric global company specializing in eBooks and audiobook entertainment, boasting a market opportunity exceeding billions of dollars. Legible’s extensive partnerships encompass four of the Big 5 Publishers and the world's largest eBook distributor, enabling it to seamlessly deliver over 2 million eBooks and audiobooks, effectively transforming any smart device into a dynamic library and eBookstore. AI & Multimedia Content: Legible’s Unbound membership service will include access to brand-new digital reading entertainment products featuring enriched multimedia content and interactive AI within groundbreaking new eBooks published exclusively by Legible.

 

Odysight.ai (OTCQB: SCTC) is pioneering the Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets with its visualization and AI platform. Providing video sensor-based solutions for critical systems in the aviation, transportation, and energy industries, Odysight.ai leverages proven visual technologies and products from the medical industry. Odysight.ai’s unique video-based sensors, embedded software, and AI algorithms are being deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases. Odysight.ai’s platform allows maintenance and operations teams visibility into areas which are inaccessible under normal operation, or where the operating ambience is not suitable for continuous real-time monitoring.

Railtown AI Technologies Inc. (CSE: RAIL) is a cloud-based Generative AI platform for Software Developers and Teams that practice Agile Project Management. Our Generative AI Co-Pilot solutions have been purposely built with a single goal in mind, to help Software Developers and Agile practitioners save time on redundant tasks, improve productivity, drive down costs and accelerate developer velocity. The Company's proprietary AI technology, designed to empower innovation and enhance quality, is accessible on Microsoft's Azure Marketplace

 

Talkspace (Nasdaq: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall healthcare and should be available to everyone. Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including live video, text or audio chat sessions and/or asynchronous text messaging. All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covers approximately 113 million lives as of September 30, 2023, through our partnerships with employers, health plans, and paid benefits programs.

 

VERSES AI Inc. (OTCQB: VRSSF; NEO: VERS) is a cognitive computing company specializing in next-generation artificial intelligence solutions. Our flagship offering, Genius™, is inspired by natural systems and human cognition. Genius can adapt, learn and integrate with the Institute of Electrical and Electronics Engineers’ open spatial web standard P2874. Key features of Genius™ include generalizability, spatial web standards integration, predictive queries, real-time adaptation and an automated computing network. Built on open standards, Genius™ transforms disparate data into knowledge models that foster trustworthy collaboration between humans, machines and AI, across digital and physical domains. Imagine a smarter world that elevates human potential through innovations inspired by nature.

 

WaveDancer, Inc. (NASDAQ: WAVD) has been servicing federal and commercial customers since 1979. WaveDancer is in the business of developing and maintaining information technology (“IT”) systems, modernizing client information systems, and performing other IT-related professional services to government and commercial organizationsFirefly is a pioneering AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. BNATM is a scalable cloud-based platform built on the company's extensive proprietary database of standardized, high-definition EEG recordings, including behavioral data. Firefly's biomarker discovery AI platform further exploits the database to discover useful biomarkers for clinicians and pharmaceutical companies. With a focus on developing state-of-the-art technologies that bridge the gap between neuroscience and clinical practice, Firefly is dedicated to transforming brain health by advancing diagnostic and treatment approaches.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411